Cytotoxic strategies which are directed to tumorassociated antigens might be most bene®cial for cancer patients with minimal tumor load such as in an adjuvant setting after initial therapy. We have recently described a highly potent single chain antibody-toxin, scFv(14E1)-ETA, which consists of the variable domains of the antibody 14E1 genetically fused to a truncated form of Pseudomonas exotoxin A. ScFv(14E1)-ETA speci®cally recognizes the human epidermal growth factor receptor (EGFR) and the oncogenically activated receptor variant EGFRvIII, which have been implicated in the development of various human malignancies. Here we have investigated the antimetastatic activity of bacterially expressed scFv(14E1)-ETA and its disul®de-stabilized derivative ds-scFv(14E1)-ETA in a novel model for disseminated disease which is based on murine renal carcinoma cells subsequently transfected with the E. coli b-galactosidase gene, and human full-length or variant EGFR cDNAs. Intravenous injection of these RencalacZ/EGFR and Renca-lacZ/EGFRvIII cells in syngenic Balb/c mice led to the formation of pulmonary metastases which were readily detectable upon excision of the lungs and X-gal staining. Systemic treatment of mice with scFv(14E1)-ETA resulted in the complete suppression of Renca-lacZ/EGFRvIII metastasis formation and drastically reduced the number of pulmonary Renca-lacZ/EGFR tumor nodules. The ds-scFv(14E1)-ETA derivative where the antibody variable regions are connected by an arti®cial disul®de bond displayed improved thermal stability at physiological temperature but due to reduced cytotoxic activity was less potent than the original scFv(14E1)-ETA in metastasis suppression.
Introduction
Micrometastatic spread of tumor cells is of prognostic relevance for patients with primary epithelial cancers (Pantel and RiethmuÈ ller, 1996) . On the surface of disseminated tumor cells in the bone marrow of cancer patients tumor-associated antigens such as the epidermal growth factor receptor (EGFR) and the closely related ErbB2 protein have been detected (Pantel et al., 1993) suggesting that therapeutic strategies directed to these receptors might allow removal of circulating tumor cells and prevent the establishment of distant metastasis (Fan and Mendelsohn, 1998) . EGFR overexpression has been implicated in the pathogenesis of multiple human tumors including glioblastoma, cancer of the lung, breast, head and neck, and bladder (Gullick, 1991) . In brain tumors such as glioblastoma (Sugawa et al., 1990; Yamazaki et al., 1990) , and in various other malignancies including non-small cell lung cancer (Garcia de Palazzo et al., 1993) , breast and ovarian carcinoma Wikstrand et al., 1995) expression of a ligand-independent, constitutively active EGFR variant, EGFRvIII has been observed. Due to gene rearrangements EGFRvIII lacks 801 nucleotides of the mature mRNA corresponding to a deletion of 267 amino acids in the EGFR extracellular domain (Sugawa et al., 1990) . This mutation creates a unique epitope in the EGFRvIII extracellular domain which distinguishes it from fulllength EGFR. Since EGFRvIII expression appears to be strictly tumor-cell speci®c it has been proposed as a target for speci®c antibodies and antibody-toxins (Hills et al., 1995; Lorimer et al., 1996; Wikstrand et al., 1995) .
Pseudomonas exotoxin A (ETA) is a potent inhibitor of protein synthesis in mammalian cells. The 66 kDa protein consists of an N-terminal cell binding domain Ia, an internal translocation domain II, a spacer region (domain Ib), and a C-terminal enzymatic domain III (Hwang et al., 1987) . After binding to target cells ETA is internalized via receptor-mediated endocytosis. Upon proteolytic activation in the acidic environment of the endosome the toxin's C-terminal eector domain translocates to the cytosol where it catalyzes the ADP-ribosylation of eukaryotic elongation factor 2 (Ogata et al., 1992) . Fusion proteins where the toxin's original cell binding domain is replaced with heterologous ligands such as growth factors or antibody domains are being investigated as potential reagents for directed cancer therapy (Pastan and FitzGerald, 1991; Wels et al., 1996) .
We have recently described a highly potent single chain antibody-toxin, scFv(14E1)-ETA, which binds speci®cally to human EGFR . ScFv(14E1)-ETA consists of the variable domains of the antagonistic monoclonal antibody (Mab) 14E1 genetically fused to a truncated form of ETA, and inhibits the in vitro growth of EGFR overexpressing established and primary tumor cells Spyridonidis et al., 1998) . In contrast to toxins employing the natural EGFR ligand TGFa as a targeting domain, scFv(14E1)-ETA also binds to the extracellular portion of the oncogenically activated receptor variant EGFRvIII and displays increased cytotoxic activity in vitro towards murine ®broblasts transfected with human EGFRvIII cDNA . Here we describe a novel tumor model based on murine renal carcinoma cells stably transfected with human full-length EGFR and variant EGFRvIII cDNAs. Intravenous injection of these tumor cells in immunocompetent Balb/c mice resulted in the formation of pulmonary metastasis which could be suppressed by systemic treatment with the recombinant anti-EGFR immunotoxin scFv(14E1)-ETA, or the disul®de-stabilized derivative ds-scFv(14E1)-ETA.
Results
Construction and bacterial expression of disul®de-stabilized antibody-toxin ds-scFv(14E1)-ETA ScFv(14E1)-ETA is a chimeric single chain antibodytoxin which consists of the variable regions of the heavy (VH) and light chains (VL) of the EGFR-speci®c Mab 14E1 connected by the synthetic linker sequence (GGGGS) 3 , and genetically fused to a truncated form of Pseudomonas exotoxin A (ETA) (Wels et al., 1992) . Since the toxin's original cell binding domain is absent in the bacterially expressed fusion protein target cell speci®city is only determined by the recombinant antibody fragment. In tissue culture experiments potent cytotoxic activity of scFv(14E1)-ETA towards established and primary human tumor cells expressing elevated EGFR levels Spyridonidis et al., 1998) , and murine cells expressing the human full-length EGFR or the oncogenically activated variant EGFRvIII has previously been observed.
In contrast to native antibodies prolonged exposure of scFv fragments to physiological temperatures can result in a loss of binding activity due to unfolding and/or aggregation (Glockshuber et al., 1990) . To increase the thermal stability of Fv antibody fragments, expression of VH and VL as separate polypeptides and subsequent crosslinking via an arti®cial disul®de bond engineered into the antibody variable regions has been suggested (Reiter et al., 1996) . Here to simplify expression and puri®cation procedures we attempted to stabilize the scFv(14E1) antibody domain by incorporating a disul®de bond between VH and VL domains, but retained the format of a single chain polypeptide where VH and VL in addition to the disul®de bond are connected by the original synthetic linker sequence (Luo et al., 1995; Young et al., 1995) . By site directed mutagenesis using PCR techniques Gln at position VH105 and Ser at position VL43 in scFv(14E1) were replaced by Cys residues (Reiter et al., 1996) (numbering according to Kabat et al. (1991) ). The resulting ds-scFv(14E1) fragment was used to replace the original scFv(14E1) domain in the plasmid pSW202-14E1 (Schmidt et al., 1997) thereby creating a vector for the expression of the modi®ed single chain antibody-toxin ds-scFv(14E1)-ETA. The construct pSW202-14E1-ds(105/43) encodes under the control of an IPTG inducible tac promoter the ds-scFv(14E1) antibody fragment fused in frame to ETA domains II, Ib and III (amino acids 252 ± 613). Upon cell binding ETA domain II mediates translocation of the toxin to the cytoplasm where domain III catalyzes the transfer of an ADP-ribose moiety from NAD to eukaryotic elongation factor 2, which results in the irreversible arrest of cellular protein synthesis (Ogata et al., 1992) .
The scFv(14E1)-ETA and ds-scFv(14E1)-ETA proteins were expressed in E. coli as described iǹ Materials and methods' and puri®ed from bacterial lysates under denaturing conditions by Ni 2+ -anity chromatography via binding of synthetic polyhistidine clusters included in the molecules . Typical yield of recombinant proteins was 2 mg/ l original culture for scFv(14E1)-ETA and 1.5 mg/l for ds-scFv(14E1)-ETA. SDS ± PAGE analysis of the puri®ed material revealed a purity of greater than 90% after a single round of anity puri®cation (data not shown).
In vitro cytotoxic activity and thermal stability of scFv(14E1)-ETA and ds-scFv(14E1)-ETA Cell killing activity of the recombinant antibody-toxins was tested on A431 human squamous carcinoma cells which express approximately 1610 6 EGF receptors per cell (Wels et al., 1995) . The cells were incubated for 40 h with increasing concentrations of scFv(14E1)-ETA or ds-scFv(14E1)-ETA, then the relative number of viable cells was determined using an enzymatic MTT assay (Wels et al., 1992) . The results are shown in Figure 1a . Both antibody-toxins displayed antitumoral activity in vitro. However, scFv(14E1)-ETA was ®ve times more potent than ds-scFv(14E1)-ETA (IC 50 values of 2.2 versus 11 ng/ml). We have previously shown that the binding anity of the scFv domain directly aects the cytotoxic activity of the scFv(14E1)-ETA antibody toxin . Here the cell killing activity of ds-scFv(14E1)-ETA was more readily blocked than that of scFv(14E1)-ETA by competition with the parental antibody 14E1 indicating that the mutations introduced in VH and VL of scFv(14E1) resulted in a molecule with reduced binding activity (data not shown).
To analyse the eect of the arti®cial disul®de bond in ds-scFv(14E1)-ETA on the thermal stability of the fusion protein, scFv(14E1)-ETA and ds-scFv(14E1)-ETA were incubated at 378C for various time intervals in cell culture medium containing 8% FBS. After preincubation the antibody-toxins were assayed for their cell killing activity on A431 cells as described above. As shown in Figure 1b in the absence of a disul®de bond connecting VH and VL, scFv(14E1)-ETA already displayed relatively high thermal stability and retained 60% of its original activity after incubation at 378C for 96 h (t 1/2 of approximately 5 days). The disul®de stabilized ds-scFv(14E1)-ETA protein displayed a signi®cantly prolonged activity half life (t 1/2 of approximately 19 days) and retained full cytotoxic activity even after 12 days at 378C. After 22 days of incubation signi®cant antitumoral activity was still observed. These data suggest that the 
Generation of Renca cell transfectants stably expressing human EGFR or EGFRvIII
Murine Renca (renal carcinoma) cells originate from a spontaneous renal cell carcinoma in Balb/c mice (Murphy and Hrusheky, 1973 ). We have previously described Renca cells stably transfected with the E. coli b-galactosidase (Renca-lacZ) or the E. coli b-galactosidase and the human c-erbB2 genes (Renca-lacZ/ ErbB2) which form pulmonary metastases upon intravenous injection into syngenic animals (MaurerGebhard et al., 1998) . Thereby due to the expression of b-galactosidase metastatic nodules can easily be detected in excised organs by X-gal staining. To establish similar models suitable for the in vivo analysis of therapeutic strategies directed to human full-length and variant EGFR, Renca-lacZ cells were stably transfected with plasmids pLTR-EGFR or pLTR-EGFRvIII (Hills et al., 1995) carrying human EGFR or EGFRvIII cDNAs, respectively. Renca cell clones expressing the human receptor proteins were identi®ed by immunoblot analysis. As shown in Figure  2a in Renca-lacZ/EGFR cells (lane 1) expression of full-length EGFR at levels comparable to human A431 cells (lane 3) was detected using 15E polyclonal anti-EGFR serum (Gullick et al., 1985) . In Renca-lacZ/ EGFRvIII cells (lane 6) expression of variant EGFRvIII at lower levels was observed upon analysis with the EGFRvIII speci®c Mab DH8.3 (Hills et al., 1995) . The previously described EGFRvIII expressing DH-ED801-P murine ®broblasts (lane 4) (Hills et al., 1995) and parental Renca-lacZ cells which do not express human EGFR proteins (lanes 2 and 5) served as controls.
To con®rm that the human receptor proteins are present on the surface of the tumor cells FACS analysis was performed. . Then the relative number of viable cells in comparison to PBS treated controls was determined using an enzymatic assay as described in Materials and methods. (b) Long-term stability of antibodytoxins. ScFv(14E1)-ETA and ds-scFv(14E1)-ETA were incubated for the indicated time intervals at a concentration of 1 mg/ml in cell growth medium supplemented with 8% FBS at 378C. Then the pretreated antibody-toxins were analysed for their cell killing activity towards A431 cells as described above. Cytotoxic activity is indicated as the percentage of initial activity without pretreatment. Each data point represents the mean of a set of data determined in triplicates EGFR proteins on the cell surface could be demonstrated using Mabs 14E1 or DH8.3, respectively. As expected, no shift in¯uorescence intensity was observed for EGFR-negative Renca-lacZ control cells.
Sensitivity of Renca cell transfectants to recombinant antibody-toxins in vitro
The sensitivity of Renca-lacZ/EGFR and Renca-lacZ/ EGFRvIII cells to treatment with the scFv(14E1)-ETA and ds-scFv(14E1)-ETA antibody-toxins was tested in cell viability assays as described above. The cells were incubated for 40 h with increasing concentrations of the puri®ed EGFR speci®c immunotoxins and the relative number of viable cells was determined. As a control, the cells were also treated with scFv(FRP5)-ETA, a similar antibody-toxin speci®c for the human ErbB2 receptor protein (Wels et al., 1992) . The results are shown in Figure 3 . Both, Renca-lacZ/EGFR and Renca-lacZ/EGFRvIII cells were highly sensitive to scFv(14E1)-ETA with IC 50 values of 1.7 and 2.8 ng/ml, respectively. The disul®de-stabilized antibody-toxin dsscFv(14E1)-ETA displayed speci®c cell killing activity, but as in the case of human A431 cells, was less active 
Formation of pulmonary metastases in Balb/c mice
To ascertain that the genetically modi®ed derivatives Renca-lacZ/EGFR and Renca-lacZ/EGFRvIII maintain the in vivo growth properties of the parental Renca cells, we investigated their ability to form pulmonary metastases in Balb/c mice. 10 5 Renca-lacZ/EGFR or Renca-lacZ/EGFRvIII cells were injected into the lateral tail vein of mice at 5 ± 6 weeks of age. At weekly intervals ®ve animals per group were sacri®ced, the lungs were excised and stained with X-gal solution to visualize disseminated tumor nodules. As shown in Figure 4a , 2 weeks after the injection of tumor cells an average number of 356+53 (s n-1 ) pulmonary metastases originating from Renca-lacZ/EGFR cells were visible on the lung surface. The number of detectable tumor nodules increased to an average of 901+167 4 weeks after tumor cell injection when the remaining animals were sacri®ced.
Renca-lacZ/EGFRvIII cells showed dierent kinetics of metastasis formation. No tumor nodules were detectable on the lung surface 2 weeks after tumor cell injection (Figure 4b ). At 3 weeks post tumor cell inoculation an average number of 60+16 tumor foci on the lung surface were visible which increased to 176+32 after 5 weeks. While Renca cells expressing full-length EGFR formed even larger numbers of pulmonary metastases than Renca-LacZ control cells (approximately 320 tumor nodules 4 weeks after injection of 10 5 cells (Maurer-Gebhard et al., 1998)), much fewer tumors arose from Renca cells expressing EGFRvIII. However, the size of Renca-lacZ/EGFRvIII tumor nodules was signi®cantly increased in comparison to Renca-lacZ/EGFR (Figure 6, left  panel) . No Renca-lacZ/EGFR or Renca-lacZ/EGFRvIII metastases were found in organs other than the lung (data not shown). (Figures 5b and 6 , middle panel). The absence of lung metastases in these animals was also con®rmed by histological analysis (Figure 7d) .
The disul®de-stabilized antibody-toxin ds-scFv(14-E1)-ETA also exhibited strong antitumoral eects in vivo, but therapeutic ecacy was signi®cantly lower than that of scFv(14E1)-ETA. In animals injected with Renca-lacZ/EGFR cells the number of pulmonary metastases was reduced to 157+11 (Figures 5a and  6 , right panel), and in animals injected with RencalacZ/EGFRvIII cells to 13+13 (Figures 5b and 6 , right panel). These results suggest that at an early time point after injection of tumor cells scFv(14E1)-ETA and, to a lesser extent ds-scFv(14E1)-ETA, are eective in eliminating circulating EGFR or EGFRvIII expressing tumor cells thereby preventing the establishment of organ metastases. No signs of systemic toxicity such as weight loss or gross organ damage were noted in any of the animals treated with either scFv(14E1)-ETA derivative (data not shown).
Formation of neutralizing antibodies in mice treated with scFv antibody-toxins
The in vivo experiments were carried out in immunocompetent animals. Therefore in mice treated with the recombinant toxins the development of ETA speci®c antibodies was expected (Altenschmidt et al., 1997) . After termination of the in vivo experiments sera were obtained from the animals to investigate their capacity to neutralize the antitumoral activity of scFv(14E1)-ETA. A431 cells were treated for 40 h with 100 ng/ml of scFv(14E1)-ETA in the presence of diluted sera. Then the relative number of viable cells in comparison to samples treated in the absence of serum was determined. As shown in Figure 8 , scFv(14E1)-ETA retained its original cytotoxic activity towards A431 cells in the presence of serum from PBS treated mice. In contrast, 1 : 500 diluted sera from animals treated either with scFv(14E1)-ETA or ds-scFv(14E1)-ETA potently inhibited the in vitro cytotoxic activity of scFv(14E1)-ETA. No eect on the growth of A431 cells was observed in the presence of sera when no antibody-toxin was present (data not shown).
Discussion
Most of the recombinant toxins currently under study as experimental anticancer drugs speci®cally recognize 5 Renca-lacZ/EGFR (a) or Renca-lacZ/EGFRvIII (b) cells were injected into the lateral tail vein of each animal. At weekly intervals ®ve mice of each group were sacri®ced and the lungs were excised. After ®xation and incubation of the organs with X-gal solution, tumor foci on the lung surface were counted as described in Materials and methods Gullick, 1991; Moscatello et al., 1995; Sugawa et al., 1990; Wikstrand et al., 1995; Yamazaki et al., 1990) . Intravenous injection in syngenic Balb/c mice of Renca cells expressing full-length EGFR or EGFRvIII results in the formation of pulmonary metastasis. We have used this system to evaluate the antimetastatic activity of the recombinant EGFR-speci®c antibodytoxin scFv(14E1)-ETA and a disul®de-stabilized derivative thereof. While some objective responses upon systemic immunotoxin treatment have been reported in patients with solid tumors (Pai et al., 1996) , it can be envisaged that recombinant toxins might be most bene®cial for the treatment of locally accessible tumors in vivo (Altenschmidt et al., 1997; Groner et al., 1997) , or for ex vivo applications such as the removal of residual tumor cells from stem cell preparations (Spyridonidis et al., 1998) , where the potent antitumoral activity can be utilized without the danger of adverse eects on normal tissues. In addition, after initial therapy the application of recombinant toxins for systemic treatment in an adjuvant setting might result in the eradication of minimal residual disease and the prevention of metastasis formation at distant sites. Thereby lower doses than those needed for the elimination of larger tumors could be eective which might limit potential adverse eects and allow achievement of therapeutic ecacy during a time period before the onset of a neutralizing antibody response towards the highly immunogenic toxin domain (Altenschmidt et al., 1997 ).
Suppression of metastases formation by an anti-EGFR immunotoxin
Here we have described a novel model system which for the ®rst time allowed investigation of the activity of an anti-EGFR immunotoxin against micrometastasis in immunocompetent animals. We have shown that derivatives of the antibody-toxin scFv(14E1)-ETA potently suppressed the formation of organ metastasis originating from circulating tumor cells expressing human EGFR or EGFRvIII. Our results demonstrate that for successful treatment the time point of toxin application is critical. While the number of RencalacZ/EGFR tumor nodules was drastically reduced, and complete suppression of Renca-lacZ/EGFRvIII metastasis formation was achieved upon treatment of mice with scFv(14E1)-ETA beginning at day 1, treatment beginning at day 11 after the inoculation of tumor cells no longer resulted in a statistically signi®cant reduction in the number of pulmonary metastases when compared to PBS treated controls (data not shown).
We have previously observed markedly increased antitumoral activity in vitro of scFv(14E1)-ETA towards murine ®broblasts expressing the oncogenically active variant EGFRvIII . Here similar cytotoxic activities in vitro of the antibody-toxin towards renal carcinoma cells transfected with either EGFR or EGFRvIII were noted. Cell type speci®c characteristics such as potential variations in the rate of receptor internalization might account for the observed dierences. Treatment with scFv(14E1)-ETA entirely suppressed the formation of Renca-lacZ/EGFRvIII metastases in vivo whereas the formation of Renca-lacZ/EGFR tumor nodules at the same dose of antibody-toxin could not be inhibited completely. While this appears to re¯ect to a major extent the dierent kinetics of Renca-lacZ/EGFR and Renca-lacZ/EGFRvIII metastasis formation, to some part it might also be due to dierences in the toxin sensitivity of tumor cells growing under in vitro or in vivo conditions. In human tumors, EGFR variants are often coexpressed with ampli®ed copies of the fulllength EGFR (Humphrey et al., 1988) . Future animal studies with Renca cells coexpressing full-length EGFR and EGFRvIII might help to clarify whether in such a situation treatment with scFv(14E1)-ETA recognizing both receptor proteins results in enhanced ecacy.
Unfolding of scFv fragments can lead to a rapid loss of binding activity under physiological conditions (Glockshuber et al., 1990) . To circumvent this problem, crosslinking of VH and VL domains in recombinant Fv antibody fragments via an arti®cial disul®de bond has been suggested as a means to stabilize the cell recognition domain of chimeric antibody-toxins (Reiter et al., 1996) . While we have indeed observed increased thermal stability of dsscFv(14E1)-ETA where Cys residues were introduced at amino acid positions VH105 and VL43, due to its lower cytotoxic activity the therapeutic eects of dsscFv(14E1)-ETA in vivo were less pronounced than those of the original scFv(14E1)-ETA. Reduced exibility of VH and VL domains in the dsscFv(14E1) derivative might aect the binding to EGFR. When Cys residues were introduced at amino acid positions VH44 and VL100 of scFv(14E1) also described to result in the generation of functional dsFv fragments (Reiter et al., 1996) , antitumoral activity of the respective ds-scFv(14E1)-ETA protein was lost completely (data not shown). This indicates that for scFv(14E1)-ETA the original format of a single chain polypeptide is preferable.
In our in vivo experiments no signs of systemic toxicity such as weight loss or gross organ damage were noted in any of the animals treated with recombinant toxins. Since scFv(14E1)-ETA is strictly speci®c for human EGFR proteins , based on these results no predictions can be made regarding possible adverse aects to be expected in humans treated with a similar regimen. However, we have previously demonstrated that in contrast to a recombinant toxin employing the natural ligand TGFa for targeting to EGFR expressing cells, similar reagents based on fragments derived from antagonistic anti-EGFR antibodies are highly selective for tumor cells expressing elevated levels of the target receptor but spare cells expressing moderate levels . Therefore a therapeutic window might be de®ned for the systemic treatment with EGFR-speci®c antibody-toxins where potential adverse eects can be prevented or limited to an acceptable range.
Materials and methods

Cell lines and cell culture
Human A431 epidermoid tumor cells were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) containing 8% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin. Mouse renal carcinoma cells (Renca cells) (Murphy and Hrushesky, 1973) were transfected with the plasmid pZeoSV2/lacZ encoding the E. To determine the activity of neutralizing antibodies, A431 squamous carcinoma cells were incubated with 100 ng/ml of puri®ed scFv(14E1)-ETA antibody-toxin in the presence of sera at a 1 : 500 dilution. After 40 h the relative number of viable cells in comparison to PBS treated controls was determined using an enzymatic assay as described in Materials and methods. Each column represents the mean of a set of data determined in triplicates coli b-galactosidase, and stable transfectants (Renca-lacZ) were selected in RPMI-1640 medium supplemented with 8% FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ ml streptomycin, 0.25 mg/ml Zeocin as described previously (Maurer-Gebhard et al., 1998) . Subsequently the Renca-lacZ cells were cotransfected with the plasmids pLTR-EGFR or pLTR-EGFRvIII (Hills et al., 1995) and pSV2neo using the calcium phosphate precipitation method. Stable transfectants were selected in RPMI-1640 medium supplemented as described above and further containing 0.48 mg/ml G418. Cell clones (Renca-lacZ/ EGFR and Renca-lacZ/EGFRvIII) were established by limiting dilution and screened for EGFR expression.
Analysis of EGFR and EGFRvIII expression
For the detection of EGFR and EGFRvIII expression by immunoblot analysis cell extracts were prepared by lysis of 2610 6 cells in 900 ml of a buer containing 0.1% SDS, 1% Triton X-100, 1% Nonidet NP 40, 150 mM NaCl, 50 mM Tris-HCl, pH 8.0, 5 mM EDTA. 20 mg each of total cellular proteins were separated by SDS ± PAGE on a 7.5% gel and electroblotted onto PVDF membranes (Millipore, Eschborn, Germany). Wild type EGFR and the receptor variant EGFRvIII were detected by incubation of the membranes with 15E anti-EGFR serum (Gullick et al., 1985) or Mab DH8.3 (Hills et al., 1995) , respectively, followed by species speci®c horseradish peroxidase coupled antibodies (Sigma, Deisenhofen, Germany) and chemiluminescent detection with the ECL kit (Amersham, Braunschweig, Germany). Expression of EGFR and EGFRvIII on the cell surface was determined by FACS analysis. 10 6 cells were incubated for 45 min with 1.5 mg of Mab 14E1 ) (Renca-lacZ/EGFR) or Mab DH8.3 (Renca-lacZ/EGFRvIII) followed by incubation with a FITC-labeled anti-mouse IgG (PharMingen, Hamburg, Germany) at a dilution of 1 : 25 for 30 min. The cells were washed twice with PBS and binding of the antibodies was detected using a FACScan (BectonDickinson, Heidelberg, Germany).
Construction of disul®de-stabilized scFv(14E1)
The scFv(14E1) encoding cDNA in the plasmid pWW152-14E1 was modi®ed by site directed mutagenesis to introduce cystein residues at amino acid positions 105 in VH and 43 in VL (Kabat et al., 1991; Reiter et al., 1996) . A VH(14E1) cDNA fragment was ampli®ed by PCR using the primers VH-Back-HindIII (5'-ATTATAAGCTTCAGGTSMARCTGCAGSAGTCWGG-3') and VH-For-105Cys (5'-AACGGTGACCGTGGTCCCACAGCC-3'). The ampli®ed PCR product was digested with HindIII and BstEII and inserted into HindIII/BstEII digested pWW152-14E1 resulting in pWW152-14E1VH105Cys. This plasmid encodes scFv(14E1) with VH105Gln mutated to a Cys residue. Subsequently, pWW152-14E1VH105Cys was used as a PCR template with VH-Back-HindIII and VL-For43Cys (5'-GAGAAGCCTTGGACAACCAT-3') as primers. The ampli®ed PCR product was digested with BstEII and StyI and subsequently inserted into BstEII/StyI digested pWW152-14E1-VH105-Cys.
The resulting plasmid pWW152-14E1-ds(VH105Cys/VL43Cys) encodes for scFv(14E1) with VH105Gln and VL43Ser mutated to Cys residues. Both mutations were con®rmed by restriction analysis and sequencing. Finally, pWW152-14E1-ds(VH105Cys/VL43Cys) was digested with HindIII and XbaI and the sequence encoding the mutated dsscFv(14E1) was inserted into HindIII/XbaI digested pSW202-14E1 resulting in pSW202-14E1-ds(105/43), an IPTG inducible expression vector encoding a fusion protein consisting of a FLAG epitope for protein detection, a cluster of 66His residues for puri®cation via Ni 2+ anity chromatography, dsscFv(14E1), another cluster of 66His and truncated Pseudomonas exotoxin A encoding amino acids 252 ± 613 (domains II, Ib, and III; Wels et al., 1992) .
Bacterial expression and puri®cation of scFv(14E1)-ETA fusion proteins E. coli HB101 carrying plasmids pSW202-14E1 or pSW202-14E1-ds(105/43) were grown in TB medium to an OD 550 of 4.5. Cells were harvested by centrifugation and resuspended in 50 ml of buer A (8 M Urea, 50 mM Tris pH 9.0, 250 mM NaCl). Cell disruption was performed in a French press followed by centrifugation at 30 0006g for 30 min at 48C. The cleared lysate was loaded onto a Ni 2+ -saturated chelating sepharose column (Pharmacia Biotech, Freiburg, Germany) equilibrated with buer A. After washing the column with buer A containing 50 mM imidazole, recombinant proteins were eluted with buer A containing 200 mM imidazole. Fractions of puri®ed fusion proteins were pooled and renatured by dialysis against PBS containing 400 mM L-arginine, followed by dialysis against PBS.
Cell viability assay
Cells were seeded in 96-well plates at a density of 10 4 cells/ well in normal growth medium. Various concentrations of fusion proteins were added to triplicate samples and the cells were incubated for 40 h. Ten ml of 10 mg/ml MTT (3-(4,5-dimethylthiazole-2-yl)-2,5 diphenyltetrazolium bromide) (Sigma) in PBS were added to each well and the cells were incubated for another 3 h. Cells were lysed by the addition of 90 ml of 20% SDS in 50% dimethyl formamide, pH 4.7. After solubilization, the absorption at 590 nm was determined in a microplate reader (Dynatech, Denkendorf, Germany) as a measure for the relative number of viable cells in comparison to cells grown without the addition of recombinant protein. To determine long-term stability of the antibody-toxins at 378C, puri®ed proteins were incubated at a concentration of 1 mg/ml for up to 22 days in DMEM medium supplemented with 8% FBS. Then the cytotoxic activity of the samples was determined as described above in comparison to protein samples stored at 48C.
Kinetics of metastasis formation in Balb/c mice
10
5 Renca-lacZ/EGFR or Renca-lacZ/EGFRvIII cells were suspended in 100 ml PBS and injected into the lateral tail vein of female Balb/c mice at 5 ± 6 weeks of age. Five animals per group were sacri®ced in weekly intervals for up to 4 (Renca-lacZ/EGFR) or 5 weeks (Renca-lacZ/EGFRvIII) post tumor cell injection. Then lungs were excised and ®xed overnight at 48C in PBS containing 2% formaldehyde and 0.2% glutaraldehyde. Fixative solution was removed and lungs were washed twice with PBS. Subsequently, the organs were incubated in a solution of 5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 63 H 2 O, 1 mM MgCl 2 , 1 mg/ml X-gal for 10 h at 378C in the dark. Metastatic nodules on the visible surface area of the lungs were counted under a dissecting microscope.
In vivo anti-tumor activity of scFv(14E1)-ETA fusion proteins Female Balb/c mice (®ve mice per group) at 5 ± 6 weeks of age were injected intravenously with 10 5 Renca-lacZ/EGFR or Renca-lacZ/EGFRvIII cells in 100 ml PBS at day 0. ScFv(14E1)-ETA fusion proteins were administered via injection into the tail vein at a daily dose of 20 mg in 100 ml of PBS from day 1 ± 10 post tumor cell injection. Control animals received PBS. Four (Renca-lacZ/EGFR) or 5 weeks (Renca-lacZ/EGFRvIII) after tumor cell injection the animals were sacri®ced and the number of pulmonary metastases was determined as described above.
